Results 211 to 220 of about 67,431 (260)

Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysis. [PDF]

Blood Cancer J
Miranda-Galvis M, Wilson J, Reategui-Almonacid Y, Johnston L, Taylor AO, Sadek R, Tjioe K, Cortes JE.   +7 more
europepmc   +1 more source

Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia. [PDF]

Leukemia
Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z.   +10 more
europepmc   +1 more source

Laparoscopic excision of proximal ileal GIST presenting with massive upper GI bleeding: a case report. [PDF]

Int J Surg Case Rep
Jha A, Adhikari S, Shrestha S, Doranga S, Mishra S, Shrestha BB.   +5 more
europepmc   +1 more source

A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study. [PDF]

Exp Ther Med
Yeh CN, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC, Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Tsai HJ, Taiwan Cooperative Oncology Group Gist Study Group.   +21 more
europepmc   +1 more source

Stemness and Survival: CD117⁺/CD133⁺ Subpopulations Sustain PI3K Signaling and Drive Imatinib Resistance in Head and Neck Mucosal Melanoma. [PDF]

Cells
Hassan SY, Santourlidis S, Flanagan TW, Hassan SL, Zhou H, Schmidt MF, Cacchi C, Lammert MF, Megahed M, Yazdi AS, Jonigk DD, Araúzo-Bravo MJ, Brodell RT, Facca S, Haikel Y, Hassan M.   +15 more
europepmc   +1 more source

Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review. [PDF]

Cancer Rep (Hoboken)
Yong KY, Lim SH, Lau LG, Chew LP.
europepmc   +1 more source

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Blood
Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A.   +20 more
europepmc   +1 more source

Imatinib and Pregnancy

Journal of Clinical Oncology, 2006
We read with great interest the article by Ault et al1 in a recent issue of Journal of Clinical Oncology, describing the results of pregnancy among patients with chronic myeloid leukemia (CML) treated with imatinib.
Ali, RIDVAN, Ozkocaman, VİLDAN, Ozkan, Atilla, Ozcelik, Tulay, Ozkalemkas, Fahir   +4 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Imatinib

Drugs, 2001
Imatinib inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukaemia (CML). Complete haematological responses were achieved in 88% of patients and major cytogenetic responses were detected in 49% of patients with chronic phase CML treated with oral imatinib 400 mg/day in a multicentre noncomparative ...
K, Lyseng-Williamson, B, Jarvis
openaire   +2 more sources

Imatinib and Hyperlipidemia

New England Journal of Medicine, 2005
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M, MANZATO, ENZO, GHERLINZONI F.   +2 more
openaire   +3 more sources